Taken together, these studies support an association between IR-expression, hypoproliferative CD8+ T cells, and favorable outcome in T1D trials of immunomodulatory agents, although the mechanisms and molecular targets of initial immune perturbation differ with each agent used. The gene discussed is CD8A; the disease is type 1 diabetes mellitus.